Healthcare Companies Report Preliminary Financial Results, Recognitions, Appointments and Company Announcements - Research Report on HCA, Sirona, WuXi PharmaTech, Allscripts, and Insulet

News provided by

Oct 23, 2013, 08:00 ET

NEW YORK, October 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting HCA Holdings, Inc. (NYSE: HCA), Sirona Dental Systems Inc. (NASDAQ: SIRO), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), and Insulet Corporation (NASDAQ: PODD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

HCA Holdings, Inc. Research Report

On October 17, 2013, HCA Holdings, Inc. (HCA) announced that it has released the Company's preliminary financial and operating results for Q3 2013. According to the release, the financial results are subject to finalization of the Company's quarterly financial and accounting procedures. Additionally, HCA stated that it anticipates Q3 2013 revenues to be approximately $8.5 billion, reflecting an anticipated increase of 4.9% YoY when compared to revenues of Q3 2012. Net income per diluted share for Q3 2013 is expected to be $0.79 per share, compared to $0.78 in Q3 2012. The Company also reported a non-GAAP adjusted EBITDA estimation of $1.6 billion compared to $1.5 billion in Q3 2012. The Full Research Report on HCA Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/be59_HCA]

Sirona Dental Systems Inc. Research Report

On October 10, 2013, Sirona Dental Systems Inc. (Sirona) announced that it has started offering the German quality T4 class instrument family for a low price, making the products interesting for dental students who can now acquire all of the important instruments they need for their studies in a student kit. According to the Company, the T4 product line has instruments which lie perfectly balanced in the dentist's hand and are ergonomically shaped, and is made of a non-slip and easy to clean material. Eric Berndt, Product Manager at Sirona, said, "This kit contains reliable and durable products at a very competitive price for students or young people who want to set up their own businesses. The T4 products fulfill Sirona's high quality requirements in terms of design as well as hygiene and ergonomics." The Full Research Report on Sirona Dental Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/08e7_SIRO]

WuXi PharmaTech (Cayman) Inc. Research Report

On October 16, 2013, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced that its genomics clinical laboratory in Shanghai has successfully passed the survey by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services relating to CLIA (Clinical Laboratory Improvement Amendments) standards, thereby receiving CLIA certification. According to WuXi PharmaTech, its laboratory is the only CLIA-certified clinical laboratory in China. In another release dated October 14, 2013, the Company stated that it will release its Q3 2013 financial results on November 12, 2013 (or November 13, 2013, Shanghai Time), after the market closes. The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/df7b_WX]

Allscripts Healthcare Solutions, Inc. Research Report

On October 17, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced that Medical Services of America (MSA) has chosen Allscripts Homecare™, to deliver a reliable and easy-to-use home care software solution with tools to assist in reducing costs, reducing hospital readmissions, and improving outcomes allowing MSA to deliver the highest quality care for patients. Commenting on the release, Martha Thorne, General Manager, Performance & Care Logistics at Allscripts, stated, "We are very pleased that MSA has been able to recognize and use the power of the Allscripts Homecare solution. Our clients understand that Allscripts Homecare is an intuitive and integrated home care solution. It is a population health solution that delivers critical data to nurses and clinicians at the point-of-care, which can be used by clinicians for smoother transitions and more effective treatment." The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1787_MDRX]

Insulet Corporation Research Report

On October 17, 2013, Insulet Corporation (Insulet) announced that it has appointed Dr. Howard Zisser, M.D., as the Company's first Medical Director. According to the Company, Dr. Zisser, as an expert in the diabetes community, will provide the Company with leadership and expertise in the clinical aspects of diabetes management, including medical input during new product development. Additionally, Dr. Zisser will also serve as Insulet's medical liaison with key opinion leaders, government officials, the U.S. Food Drug Administration (FDA) staff and healthcare organizations. Commenting on the new appointment, Duane DeSisto, President and CEO of Insulet said, "Howard's clinical expertise in current and emerging diabetes technologies is unparalleled and we are proud to have him join the Insulet team as our first Medical Director. With a distinguished background working on innovative diabetes therapies, including extensive research on artificial pancreas systems, Howard will be a major catalyst as we continue development of new products at Insulet. We are delighted to have him help the Company drive these programs toward commercialization." The Full Research Report on Insulet Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/75e4_PODD]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner